These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35269731)

  • 1. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer.
    Ton AT; Foo J; Singh K; Lee J; Kalyta A; Morin H; Perez C; Ban F; Leblanc E; Lallous N; Cherkasov A
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
    Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
    Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
    Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
    Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
    Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
    Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
    Hsu EC; Shen M; Aslan M; Liu S; Kumar M; Garcia-Marques F; Nguyen HM; Nolley R; Pitteri SJ; Corey E; Brooks JD; Stoyanova T
    Sci Rep; 2021 Jun; 11(1):13305. PubMed ID: 34172788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.
    Bhattacharya S; Harris HL; Islam R; Bodas S; Polavaram N; Mishra J; Das D; Seshacharyulu P; Kalluchi A; Pal A; Kohli M; Lele SM; Muders M; Batra SK; Ghosh PM; Datta K; Rowley MJ; Dutta S
    Cell Death Dis; 2024 Aug; 15(8):617. PubMed ID: 39183332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
    Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
    J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
    Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
    Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Turpin A; Delliaux C; Parent P; Chevalier H; Escudero-Iriarte C; Bonardi F; Vanpouille N; Flourens A; Querol J; Carnot A; Leroy X; Herranz N; Lanel T; Villers A; Olivier J; Touzet H; de Launoit Y; Tian TV; Duterque-Coquillaud M
    Br J Cancer; 2023 Dec; 129(12):1903-1914. PubMed ID: 37875732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
    Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
    Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
    Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
    Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.
    Wang Y; Scurll J; Rascón IA; Cui C; Ni Y; Shi AM; Gangadharannambiar P; Wang Y; Akamatsu S; Beltran H; Cox M; Crea F; Daugaard M; Dong X; Haffner M; He H; Jachetti E; Kyprianou N; Li B; Ong CE; Rickman DS; Sen T; Zhu HH; Zoubeidi A; Gleave ME
    Epigenomics; 2024; 16(17):1129-1132. PubMed ID: 39225130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
    Weissenrieder JS; Reilly JE; Neighbors JD; Hohl RJ
    Prostate; 2019 Jan; 79(1):21-30. PubMed ID: 30106164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.